Breast cancer immunotherapy and personalized medicine






Review Article

American Journal of BioMedicine
Volume 10, Issue 4, October 21 2022, Pages 146-158 | http://dx.doi.org/10.18081/2333-5106/2022.10/146

Kishwer R Pinsky 1, Emily V Pichard 1, Ahmad J Sahib 1, 2, Andrea F Risch 1*

Author Affiliations
*Correspondence author e-mail: Rischfa@gmail.com : 1 Department of Biological Sciences, Northern Illinois University, USA. 2 Department of Medical Oncology, Cairo University, Egypt.

Received  May 11 2022   Revised  July 30 2022   Accepted  September 22 2022   Published  October 21 2022

 

Abstract

Breast cancer response to immunotherapy is succussed; however, the evaluation of sensitive/resistant target treatment subpopulations based on stratification by tumor biomarkers may improve the predictiveness of response to immunotherapy. Treatment decisions which were based in the past predominantly on the anatomic extent of the disease are shifting to the underlying biological mechanisms. Gene array technology has led to the recognition that breast cancer is a heterogeneous disease composed of different biological subtypes, and genetic profiling enables response to chemotherapy to be predicted. Biological therapy has been developed to target HER2 receptor and combination of antibody drug conjugates linked cytotoxic therapy to HER2 antibodies. This review will give a general overview of the impact of breast cancer and the role of immunotherapy in breast cancer as well as studying tumor biomarkers that increase the likelihood of success with immunotherapy in breast cancer.

Keywords: Breast cancer; Immunotherapy; Sensitive/resistant target treatment

Copyright © 2022 Andrea F Risch, et al. This article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to citeReferencesDownload citationStatistics
The citation data is computed by the following citation measuring services:

RIS
Hidden content
EndNote
Hidden content
Mendeley
Hidden content
BibTeX
Hidden content
APA
Hidden content
MLA
Hidden content
HARVARD
Hidden content
VANCOUVER
Hidden content

  1. Yager JD Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354:270-282.
    https://doi.org/10.1056/NEJMra050776
  2. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350:1047-1059. https://doi.org/10.1016/S0140-6736(97)08233-0
  3. Brinton LA Richesson D Leitzmann MF et al. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev. 2008; 17:3150-3160. https://doi.org/10.1158/1055-9965.EPI-08-0435
  4. Chlebowski RT Anderson GL Pettinger M et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med 2008; 168:370-377. https://doi.org/10.1001/archinternmed.2007.123
  5. Burstein HJ Prestrud AA Seidenfeld J et al. The American Society of Clinica OncologyAmerican Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28:3784-3796. https://doi.org/10.1200/JCO.2009.26.3756
  6. Pitteri SJ Hanash SM Aragaki A et al. Postmenopausal estrogen and progestin effects on the serum proteome. Genome Med 2009; 1:121. https://doi.org/10.1186/gm121
  7. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131:18-43. https://doi.org/10.5858/2007-131-18-ASOCCO
  8. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69:9330-9336. https://doi.org/10.1158/0008-5472.CAN-08-4597
  9. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 2007; 26:3637-3643. https://doi.org/10.1038/sj.onc.1210379
  10. Rabindran SK, Discafani CM, Rosfjord EC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004;64: 3958-3965. https://doi.org/10.1158/0008-5472.CAN-03-2868
  11. Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2:127-137. https://doi.org/10.1016/S1535-6108(02)00097-1
  12. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28:1138-1144. https://doi.org/10.1200/JCO.2009.24.2024
  13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216. https://doi.org/10.1093/jnci/92.3.205
  14. Valero V, Forbes J, Pegram MD, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 2011; 29:149-156. https://doi.org/10.1200/JCO.2010.28.6450
  15. Yuan Y, Failmezger H, Rueda OM, et al. Quantitative image analysis of cellular heterogeneity in breast tumours complements genomic profiling. Sci Transl Med 4:157ra143. https://doi.org/10.1126/scitranslmed.3004330
  16. Simon R: Development and validation of therapeutically relevant multi-gene biomarker classifiers. J Natl Cancer Inst 2005; 97:866-867. https://doi.org/10.1093/jnci/dji168
  17. Rhodes A, Jasani B. The oestrogen receptor-negative/progesterone receptor-positive breast tumour: a biological entity or a technical artefact? J Clin Pathol 2009; 62(1):95-96. https://doi.org/10.1136/jcp.2008.060723
  18. Pagani O, Francis PA, Fleming GF, et al. Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: results from TEXT and SOFT. J Clin Oncol 2020; 38(12):1293-1303. https://doi.org/10.1200/JCO.18.01967
  19. Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005; 23(30):7512-7517. https://doi.org/10.1200/JCO.2005.01.4829
  20. Al-Amran F, and Hassan Al-khirsani. Journal of Clinical Oncology 2012 30:4_suppl, 59-59. https://doi.org/10.1200/jco.2012.30.4_suppl.59
  21. Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012; 30(8):777-782. https://doi.org/10.1200/JCO.2011.36.1196
  22. Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005; 97(17):1254-1261. https://doi.org/10.1093/jnci/dji249
  23. Prat A, Cheang MC, Martín M, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 2013; 31(2):203-209. https://doi.org/10.1200/JCO.2012.43.4134
  24. Danielson AD, Wang DG, et al. Letrozole versus anastrozole in postmenopausal women with chemotherapy-refractory negative HER-2 metastatic breast cancer: a randomized, multicenter, open-label, non-inferiority phase 3 study. American Journal of BioMedicine 2015; 3(1):57-64. https://doi.org/10.18081/2333-5106/014-4/431-440
  25. Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010; 468(7320):103-107. https://doi.org/10.1038/nature09495
  26. Malbeteau L, Poulard C, Languilaire C, et al. PRMT1 is critical for the transcriptional activity and the stability of the progesterone receptor. iScience 2020; 23(6):101236. https://doi.org/10.1016/j.isci.2020.101236
  27. Chung H, Sze S, Tay A, Lin VJ. Acetylation at lysine 183 of progesterone receptor by p300 accelerates DNA binding kinetics and transactivation of direct target genes. J Biol Chem 2014; 289(4):2180-2194. https://doi.org/10.1074/jbc.M113.517896
  28. Pedroza DA, Subramani R, Lakshmanaswamy R. Classical and non-classical progesterone signaling in breast cancers. Cancers 2020; 12(9):2440. https://doi.org/10.3390/cancers12092440
  29. Asavasupreechar T, Saito R, Miki Y, Edwards DP, Boonyaratanakornkit V, Sasano H. Systemic distribution of progesterone receptor subtypes in human tissues. J Steroid Biochem Mol Biol 2020; 199:105599. https://doi.org/10.1016/j.jsbmb.2020.105599
  30. Starvaggi Cucuzza L, Divari S, Mulasso C, Biolatti B, Cannizzo FT. Regucalcin expression in bovine tissues and its regulation by sex steroid hormones in accessory sex glands. PLoS One 2014; 9(11):e113950. https://doi.org/10.1371/journal.pone.0113950
  31. Mallepell S, Krust A, Chambon P, Brisken C. Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci U S A 2006; 103(7):2196-2201. https://doi.org/10.1073/pnas.0510974103
  32. Tan H, Yi L, Rote NS, Hurd WW, Mesiano S. Progesterone receptor-A and -B have opposite effects on proinflammatory gene expression in human myometrial cells: implications for progesterone actions in human pregnancy and parturition. J Clin Endocrinol Metab 2012; 97(5):E719-E730. https://doi.org/10.1210/jc.2011-3251
  33. Recouvreux MS, Diaz Bessone MI, Taruselli A, et al. Alterations in progesterone receptor isoform balance in normal and neoplastic breast cells modulates the stem cell population. Cells 2020; 9(9):2074. https://doi.org/10.3390/cells9092074
  34. Yousif NG, Al-Matwari M. Overexpression of Notch-1 induced tamoxifen resistance through down regulation of ESR1 in positive estrogen receptor breast cancer. Journal of clinical oncology 2012; 30(15_suppl): e11046-e11046. https://doi.org/10.1200/jco.2012.30.15_suppl.e11046
  35. AI-Timimi A. Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: pathological correlation and prognostic indicators. American Journal of BioMedicine 2016; 4(3):265-275.

1. Access through OpenAthens

2. PDF     XML

For any technique error please contact us.

Downloads: 113

 

Downloads: 113

      PDF           XML

How to cite this article
Pinsky KR, Pichard EV, Sahib AJ, Risch AF. Breast cancer immunotherapy and personalized medicine. American Journal of BioMedicine. 2022; 10(4):146-158

Article metric

Archives